COMMUNIQUÉS West-GlobeNewswire

Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer

27/12/2017 - 14:30

Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM, Mass., Dec. 27, 2017 ( [...]

Agritek Holdings, Inc. Announces $1,000,000 Capital Infusion With Institutional Investor And Eliminates First $200,000 Of Existing Toxic Convertible Debt With Final $500,000 In Convertible Debt To Be Paid By Year End.

27/12/2017 - 14:30

LOS ANGELES, CA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Agritek Holdings, Inc. (OTCQB: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector and consultant for multiple [...]

Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases

27/12/2017 - 14:30

CAMBRIDGE, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]

Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel

27/12/2017 - 14:00

BUFFALO, N.Y., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme

27/12/2017 - 14:00

CHARLOTTESVILLE, Va., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of [...]

Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial

27/12/2017 - 13:30

BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data [...]

Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron

27/12/2017 - 13:30

UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced [...]

Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission

27/12/2017 - 13:30

CARMIEL, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]

ProQR Announces Extraordinary General Meeting of Shareholders

27/12/2017 - 13:00

LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR ), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16: [...]

Blood donors step up, but more still needed

27/12/2017 - 13:00

OTTAWA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Canadian Blood Services has seen a notable increase in donations since Dec. 18 when it issued an urgent call for eligible donors to fill 35,000 open appointments by Jan. 6. [...]

VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.

27/12/2017 - 13:00

TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB [...]

Medigus Announces First MUSE(TM) Procedure for the Treatment of GERD Performed in Israel at Shaare-Zedek Medical Center

27/12/2017 - 13:00

OMER, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, [...]

Novo Nordisk A/S: Share repurchase programme

27/12/2017 - 11:43

Bagsværd, Denmark, 27 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Orion Corporation: Managers' transactions - Westerlund Riikka

27/12/2017 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 27 DECEMBER 2017 at 9.45 EET Orion Corporation: Managers' transactions - Westerlund Riikka Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Herantis Pharma expands on timeline for Lymfactin studies

27/12/2017 - 08:01

Herantis Pharma expands on timeline for Lymfactin® studies Herantis Pharma Plc Company release 27 December 2017 at 9:00 am Herantis Pharma Plc's ("Herantis") announces a slight delay in completing patient recruitment in [...]

NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION

27/12/2017 - 07:01

REGULATED INFORMATION GHENT, Belgium, 27 December 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Jefferies [...]

NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial

26/12/2017 - 23:30

FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]

NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix

26/12/2017 - 23:30

LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]

NANOBIOTIX : 2017 review and 2018 expected milestones

26/12/2017 - 23:27

Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]